BUZZ-BioMarin Pharma shares fall after lowering annual performance expectations

November 2 - ** BioMarin Pharmaceutical (BMRN.O) shares fell 6.9% in after-hours trading to $53.50

** The pharmaceutical company lowered its 2026 earnings per share forecast to a range of $2.80 to $3.10, down from the previous range of $4.90 to $5.10

** BMRN expects its 2026 annual sales to be in the range of $3.80 billion to $3.90 billion, compared to the earlier forecast of $3.875 billion to $3.925 billion

** The company said the updated revenue guidance reflects delivery timing uncertainties related to several orders from a single international customer

** The Alesta acquisition (link) and the BMN 450 licensing agreement are expected to result in about $320 million and $83 million in pre-tax charges respectively in 2026, reducing earnings per share (EPS) by approximately $1.55 and $0.32 respectively

** BMRN reported third-quarter revenue of $1.025 billion, slightly below analysts' estimates of $1.026 billion — according to LSEG data

** Third-quarter sales of its genetic disease drug Voxzogo were $245 million, below the expected $257 million

** As of the last close, the stock was down 3.3% year-to-date

(To facilitate non-English speakers, Reuters has automatically translated its reporting into several other languages. Since automated translation may contain errors or lack context, Reuters does not guarantee the accuracy of the automated translation and provides it for readers' convenience only. Reuters assumes no responsibility for any harm or losses resulting from the use of automated translation.)